NO-synthase inhibition in sepsis

• References

• 1 Guidet B, Aegerter P, Gauzit R. et al. Incidence and impact of organ dysfunctions associated with sepsis. Chest 2005; 127: 942-51.
• 2 Tracey KJ, Fong Y, Hesse DG. et al. Anti-cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
• 3 Norman JG, Sutton ET, Franz MS. et al. Maintenance of dynamic microvascular function and structure in a rat model of endotoxic shock by blockade of the interleukin-1 receptor. Shock 1995; 03: 369-75.
• 4 Abraham E, Laterre PF, Garbino J. et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29: 503-10.
• 5 Fisher CJ, Dhainaut JF, Opal SM. et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
• 6 Cunha FQ, Assreuy J, Moss DW. et al. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. Immunology 1994; 81: 211-5.
• 7 Gunnett CA, Chu Y, Heistad DD. et al. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol 1998; 275: H416-21.
• 8 Hock CE, Yin K, Yue G, Wong PY. Effects of inhibition of nitric oxide synthase by aminoguanidine in acute endotoxemia. Am J Physiol 1997; 272: H843-50.
• 9 Levy B, Valtier M, de Chillou C. et al. Beneficial effects of L-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. Shock 1999; 11: 98-103.
• 10 Rosselet A, Feihl F, Markert M. et al. Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 1998; 157: 162-70.
• 11 Petros A, Lamb G, Leone A. et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
• 12 Lopez A, Lorente JA, Steingrub J. et al. Multiplecenter, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30.
• 13 Pullamsetti SS, Maring D, Ghofrani HA. et al. Effect of nitric oxide synthase (NOS) inhibition on macro-and microcirculation in a model of rat endotoxic shock. Thromb Haemost 2006; 95: 720-7.
• 14 Morin MJ, Unno N, Hodin RA. et al. Differential expression of inducible nitric oxide synthase messenger RNA along the longitudinal and crypt-villus axes of the intestine in endotoxemic rats. Crit Care Med 1998; 26: 1258-64.
• 15 Zhang H, Rogiers P, Smail N. et al. Effects of nitric oxide on blood flow distribution and O2 extraction capabilities during endotoxic shock. J Appl Physiol 1997; 83: 1164-73.
• 16 Sakr Y, Dubois MJ, De Backer D. et al. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004; 32: 1825-31.
• 17 De Backer D, Creteur J, Preiser JC. et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166: 98-104.
• 18 Lam C, Tyml K, Martin C. et al. Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 1994; 94: 2077-83.